Articles Archives - Page 396 of 733

MondayJul 12, 2021 1:03 pm

Q1 Productions’ 2nd Annual Medical Device Biocompatibility & Toxicology Risk Assessment Conference To Offer Safe Medical Testing Strategies For Commercial Markets

Date: July 21-23, 2021 Virtual Event Companies and professionals from the biocompatibility, toxicology, materials engineering, and related medical fields are invited to attend the Q1 Productions’ 2nd Annual Medical Device Biocompatibility & Toxicology Risk Assessment Conference being held on July 21-23, 2021. Industry leaders and regulatory authorities will share presentations discussing compliant design and commercialization evaluation processes for medical device professionals to develop safe testing strategies. This online streaming conference is a great opportunity for you to meet and collaborate with industry professionals to ensure your products meet biological safety requirements as per the global safety standards. The event will…

MondayJul 12, 2021 12:31 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023 For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the…

MondayJul 12, 2021 12:20 pm

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Is ‘One to Watch’

Avricore Health Inc. is a pharmacy solutions provider that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues The company’s wholly owned subsidiary, HealthTab, offers fast, accurate and cost-effective point-of-care screening Its current test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR); HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19 The company leverages strategic partnerships with notable names in the diagnostic space, including Abbott Rapid Diagnostics, to offer high quality,…

MondayJul 12, 2021 11:17 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists from CSE to Focus Efforts on Most Effective Drug Platform Outcomes

Lexaria Bioscience is a drug bioavailability platform developer intent on providing an effective oral administration alternative to smoking that duplicates the rapid assimilation benefits of inhalation without the lung-harmful effects The company’s DehydraTECH IP is being evaluated for concentration levels, tolerability and ability to transform partner drugs to oral solutions without incidentally creating new molecular entities Lexaria announced voluntary delisting from the Canadian Securities Exchange this month in order to focus its resources more effectively on its Nasdaq listing The company’s leadership recently interacted with investors in the Life Sciences Investor Forum virtual conference series and the company’s annual meeting…

FridayJul 09, 2021 11:14 am

Ideanomics Inc. (NASDAQ: IDEX) EV Tractor Subsidiary Names CEO as EV Market Continues Global Growth, Evolution

Zero-emissions electric tractor manufacturer Solectrac recently announced that agriculture and construction industry veteran Mani Iyer will succeed the company’s founder as CEO as Solectrac enters an anticipated period of new growth Solectrac is a subsidiary of clean energy-focused company Ideanomics Inc., which announced its 100 percent acquisition of the EV tractor manufacturer and distributor last month The electric vehicle (“EV”) market continues its push toward maturity as many of the world’s governments struggle to enact systemic change to their energy policies as a response to persistent concerns about the global climate (https://ibn.fm/9iw8G). New York-based EV company Ideanomics (NASDAQ: IDEX) is…

FridayJul 09, 2021 10:52 am

FingerMotion Inc. (FNGR) Continues to Push the Envelope in the Insurance Industry with Latest Subsidiary Partnership

FingerMotion’s subsidiary Xunlian Tianxia Technology entered into an agreement with Happy Life Insurance to create an innovative, data-driven insurance business model The model aims to develop new insurance products that can address real consumers’ needs by combining Xunlian’s data mining and customer profiling experience with Happy Life’s insurance expertise The new collaboration follows a similar announcement earlier this year in which FingerMotion partnered with Pacific Life Re-Insurance FingerMotion expects multiple contracts relating to its insurtech products before the end of calendar 2021 New technologies such as big data, blockchain, the Internet of Things (“IoT”), artificial intelligence (“AI”), and cloud computing…

FridayJul 09, 2021 10:27 am

Emaginos Inc. Files Patent for Exclusive Educational Analytics Platform

Company files provisional patent for EdManage Analytics Platform with US patent office EdManage carefully aggregates individual parts into new entity that provides insightful, useful and actionable information Emaginos believes its EdManage system has potential to make a profound impact on education Emaginos, a REG-A public company (please see website if interested in investing) in the business of transforming K-12 public education, has filed a patent for its EdManage Analytics Platform (https://ibn.fm/EzYJ5). Emaginos announced earlier this month that it had filed a provisional patent application, titled “Education Analytics Platform,” with the United States Patent and Trademark Office for its proprietary analytics…

ThursdayJul 08, 2021 1:00 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company

Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs It is one of only a handful of companies moving into Phase 2a clinical trials with a psychedelic compound, and seeks to duplicate the success of GW As of 2020, the global biotech sector was valued at $753 billion. It is further projected to grow at…

ThursdayJul 08, 2021 12:38 pm

Infobird Co., Ltd (NASDAQ: IFBD) and its Influence on China’s SaaS Market

SMEs account for about 60% of China’s production GDP However, they have a relatively low adoption of SaaS and automation tools Infobird, through innovation and education, is trying to rectify this issue By targeting these SMEs, it will be impacting the entire Chinese SaaS market, positioning it as a global leader As of 2019, the Chinese software-as-a-service SaaS market was estimated between $3.7 billion and $6 billion in value (https://ibn.fm/NBymg). That was just 6% less than the total value of the global SaaS market. This is great for the country. However, when compared to other nations such as the United…

ThursdayJul 08, 2021 11:38 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive Results From its Recent Animal Study on the Effectiveness of its DehydraTECH Drug Delivery Technology

Lexaria Bioscience Corp. announced positive results from its VIRAL-A20-2 study This study showed strong gains in delivery of the DehydraTECH-enabled remdesivir and ebastine among animals The success of this study shows the potential and commercial viability of Lexaria’s DehydraTECH In June 2021, Lexaria Bioscience (NASDAQ: LEXX) announced positive results from its VIRAL-A20-2 study that evaluated the effectiveness of DehydraTECH-enabled remdesivir and ebastine among animals. The results were strongly positive and demonstrated greater effectiveness than in Lexaria’s first antiviral drug study reported in December 2000. The research was a tolerability and pharmacokinetic (“PK”) study involving four groups of 10 animals each.…

Site Search

Company Search

Category: Articles